Amendment No. 2 to SC 13G

0001193125-17-111513.txt : 20170405 0001193125-17-111513.hdr.sgml : 20170405 20170405144055 ACCESSION NUMBER: 0001193125-17-111513 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170405 DATE AS OF CHANGE: 20170405 GROUP MEMBERS: LYDA HILL GROUP MEMBERS: MALACHITE TRUST SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Bioptix, Inc. CENTRAL INDEX KEY: 0001167419 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 841553387 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-79102 FILM NUMBER: 17742208 BUSINESS ADDRESS: STREET 1: 834-F SOUTH PERRY STREET, SUITE 443 CITY: CASTLE ROCK STATE: CO ZIP: 80104 BUSINESS PHONE: 303-794-2000 MAIL ADDRESS: STREET 1: 834-F SOUTH PERRY STREET, SUITE 443 CITY: CASTLE ROCK STATE: CO ZIP: 80104 FORMER COMPANY: FORMER CONFORMED NAME: Venaxis, Inc. DATE OF NAME CHANGE: 20121218 FORMER COMPANY: FORMER CONFORMED NAME: AspenBio Pharma, Inc. DATE OF NAME CHANGE: 20051110 FORMER COMPANY: FORMER CONFORMED NAME: ASPENBIO INC DATE OF NAME CHANGE: 20020213 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Remeditex Ventures LLC CENTRAL INDEX KEY: 0001627363 IRS NUMBER: 452451953 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 BUSINESS PHONE: (214) 506-2662 MAIL ADDRESS: STREET 1: 2101 CEDAR SPRINGS ROAD, SUITE 601 CITY: DALLAS STATE: TX ZIP: 75201 SC 13G/A 1 d370429dsc13ga.htm AMENDMENT NO. 2 TO SC 13G Amendment No. 2 to SC 13G

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

(Rule 13d-102)

Information to be Included in Statements filed Pursuant to Rule

13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2

(Amendment No. 2)*

BIOPTIX, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

92262A206

(CUSIP NUMBER)

March 31, 2017

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Cusip No. 92262A206		Page 2 of 8 Pages

SCHEDULE 13G


1.	Name of Reporting Persons: Remeditex Ventures LLC
2.	Check the appropriate box if a member of a group (a) ☐ (b) ☒ (joint filers)
3.	SEC Use Only.
4.	Citizenship or Place of Organization Texas
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 0
9.	Aggregate amount beneficially owned by each reporting person 0
10.	Check box if the aggregate amount in row 9 excludes certain shares ☐
11.	Percent of class represented by amount in row 9 0%
12.	Type of Reporting Person OO


Cusip No. 92262A206		Page 3 of 8 Pages

SCHEDULE 13G


1.	Name of Reporting Persons: Malachite Trust
2.	Check the appropriate box if a member of a group (a) ☐ (b) ☒ (joint filers)
3.	SEC Use Only.
4.	Citizenship or Place of Organization Texas
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 0
9.	Aggregate amount beneficially owned by each reporting person 0
10.	Check box if the aggregate amount in row 9 excludes certain shares ☐
11.	Percent of class represented by amount in row 9 0%
12.	Type of Reporting Person OO


Cusip No. 92262A206		Page 4 of 8 Pages

SCHEDULE 13G


1.	Name of Reporting Persons: Lyda Hill
2.	Check the appropriate box if a member of a group (a) ☐ (b) ☒ (joint filers)
3.	SEC Use Only.
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 0
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 0
9.	Aggregate amount beneficially owned by each reporting person 0
10.	Check box if the aggregate amount in row 9 excludes certain shares ☐
11.	Percent of class represented by amount in row 9 0%
12.	Type of Reporting Person IN


Cusip No. 92262A206		Page 5 of 8 Pages

SECURITIES AND EXCHANGE COMMISSION

SCHEDULE 13G

Item 1(a).

Name of Issuer:

Bioptix, Inc.

Item 1(b).

Address of Issuer’s Principal Executive Offices:

1775 38^th Street, Boulder, CO 80301

Item 2(a).

Name of Person Filing:

This statement is filed on behalf of (1) Remeditex Ventures LLC, (2) Malachite Trust and (3) Lyda Hill.

Item 2(b).

Address of Principal Business Office or, if none, Residence:

2727 N. Harwood St.

Suite 200

Dallas, Texas 75201

Item 2(c).

Citizenship:

Remeditex Ventures LLC and Malachite Trust – Texas

Lyda Hill - United States of America.

Item 2(d).

Title of Class of Securities:

Common Stock, no par value (the “Common Stock”)

Item 2(e).

CUSIP Number.

The Issuer’s CUSIP Number is 92262A206

Item 3.

If this Statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), or (c), check whether the person filing is a:

Not Applicable.

Item 4.

Ownership.


(a)	Amount beneficially owned:

	Remeditex Ventures LLC	0
	Malachite Trust	0
	Lyda Hill	0


Cusip No. 92262A206		Page 6 of 8 Pages



(b)	Percent of Class:

	Remeditex Ventures LLC	0%
	Malachite Trust	0%
	Lyda Hill	0%



(c)	Number of shares as to which such person has:

	(i)	Sole power to vote or to direct the vote:

		Remeditex Ventures LLC	0
		Malachite Trust	0
		Lyda Hill	0

	(ii)	Shared power to vote or to direct the vote:

		Remeditex Ventures LLC	0
		Malachite Trust	0
		Lyda Hill	0

	(iii)	Sole power to dispose or to direct the disposition of:

		Remeditex Ventures LLC	0
		Malachite Trust	0
		Lyda Hill	0

	(iv)	Shared power to dispose or to direct the disposition of:

		Remeditex Ventures LLC	0
		Malachite Trust	0
		Lyda Hill	0

Item 5.

Ownership of Five Percent or Less of a Class.

This Schedule 13G/A is being filed to report that the reporting person has as of March 31, 2017, ceased to be the beneficial owner of more than 5% of the Common Stock of Bioptix, Inc. ☒.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

Not Applicable.


Cusip No. 92262A206		Page 7 of 8 Pages

Item 8.

Identification and Classification of Members of the Group.

Not Applicable.

Item 9.

Notice of Dissolution of Group.

Not Applicable.

Item 10.

Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits:

Exhibit 1* —

Joint Filing Agreement, dated September 19, 2016, by and among Remeditex Ventures LLC, Malachite Trust and Lyda Hill.

*	Previously filed as an Exhibit to the Schedule 13G filed on September 19, 2016.


Cusip No. 92262A206		Page 8 of 8 Pages

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 5, 2017


Remeditex Ventures LLC

By:		/s/ Brett Ringle
		Brett Ringle, President

Malachite Trust

By:		/s/ Lyda Hill
		Lyda Hill, Trustee

/s/ Lyda Hill
		Lyda Hill